InnoScience (Suzhou) Technology Holding Co., Ltd. 2025 Annual Report: Key Highlights, Risks, and Shareholder Alerts

Executive Summary

InnoScience (Suzhou) Technology Holding Co., Ltd. (“InnoScience” or the “Company”), a leading Si-based GaN power device IDM enterprise, has released its 2025 Annual Report. The document provides an in-depth overview of the Company’s financial health, operational activities, risk exposures, corporate governance, and significant events that may materially affect shareholder value and the Company’s share price.

Key Financial Highlights & Business Performance

• Liquidity and Capital Resources: As of December 31, 2025, the Group held RMB879.0 million in cash and cash equivalents, down from RMB1,525.0 million a year earlier. The reduction is primarily attributed to strategic investments in large-denomination negotiable certificates of deposit (CDs) and increased borrowings.
• Investment in Wealth Management Products: The Group invested RMB1,636.7 million in large-denomination negotiable CDs for fund management purposes. These investments are considered low-risk and offer higher returns than conventional time deposits. However, a portion of these investments with China Resources Bank exceeded the 5% applicable percentage ratio, thus constituting a discloseable transaction under Hong Kong’s Listing Rules.
• Significant Net Outflow: The Group reported a net outflow of cash from operating activities totaling RMB806.4 million in 2025.
• Financial Ratios:
  • Current Ratio: Increased from 2.5x to 5.3x, reflecting higher current assets driven by capital inflows and business expansion.
  • Quick Ratio: Rose from 2.0x to 4.2x, indicating improved liquidity but also due to increased receivables and investments.
  • Net Gearing Ratio: Jumped from 13.4% to 32.1%, mainly due to lower cash balances (resulting from investments in CDs) and increased borrowings.
• Revenue & Profitability: The Company continues to invest in expanding its 8-inch GaN wafer production capacity, R&D, and global distribution network. No dividend was declared for 2025, reflecting a reinvestment strategy.

Potential Price-sensitive Developments & Risks

• Regulatory Breaches and Internal Controls Weakness:
  • The Company failed to fully comply with Listing Rules regarding the disclosure and use of proceeds for investments in wealth management products. It mistakenly classified such investments as time deposits, leading to a deviation from the intended use of IPO and placement proceeds.
  • Immediate corrective actions are underway, including withdrawal from wealth management products, strengthened internal reporting, and enhanced compliance training for staff and directors.
  • The Board acknowledges that the effectiveness of internal controls requires further improvement, particularly in compliance, reporting, and proceeds management.
• Litigation Risks: The Company is a respondent in several ongoing legal disputes in the US and Germany (EPC California Case, Infineon California & Germany Cases) relating to alleged IP infringements. While outcomes are uncertain, these could have material financial implications.
• Disclosure of Connected Transactions:
  • The Group engaged in significant connected transactions with China Merchants Bank and its affiliates, including deposit, loan, and wealth management transactions. All were within the approved caps, but continued monitoring and adherence to independent shareholders’ approval and reporting requirements is critical.
• Use of Proceeds from Listings and Placings:
  • Global Offering (IPO): Net proceeds of HK\$1,351.96 million allocated to capacity expansion, R&D, network expansion, and working capital. A portion was inadvertently invested in wealth management products, but will be redirected as per original plans by June 2026.
  • First H Share Placing: Raised HK\$543.55 million, with a similar deviation in use of proceeds, which has since been rectified.
  • Second H Share Placing: Raised HK\$1,550.43 million, again with proceeds used in CDs/wealth management products. Correction in process, all to be resolved by June 2026.
• Corporate Governance & Shareholder Rights:
  • The Company has made several amendments to its Articles of Association, including abolishing the Supervisory Committee and assigning its functions to the Audit Committee. This may affect oversight and governance structures.
  • Shareholders holding >10% can convene extraordinary meetings, and those with >1% can submit interim proposals.
• Currency and Interest Rate Risks:
  • The Company faces significant exposure to fluctuations in USD and HKD against RMB. A 3% change in USD/RMB would affect losses by approximately RMB19.7 million, and in HKD/RMB by approximately RMB4.1 million.
  • No hedging contracts were in place as of year-end 2025.
• Environmental, Social, and Governance (ESG):
  • The Company achieved a 5% reduction in electricity consumption per million revenue, and invested in staff development, diversity, and energy-saving initiatives.
  • Donations for the year totaled RMB2.83 million.

Critical Shareholder Alerts

• Compliance Lapses: The failure to comply with Listing Rules on the use and disclosure of proceeds is a material event. If not swiftly and thoroughly rectified, it could attract regulatory scrutiny, penalties, or undermine investor confidence, potentially pressuring the share price.
• Legal Proceedings: Ongoing litigation involving intellectual property rights in the semiconductor sector could lead to substantial financial liabilities or settlement costs, influencing future profitability and valuation.
• No Dividend Declared: The absence of a dividend for 2025 signals a reinvestment phase but may disappoint income-focused investors.
• Governance Restructuring: Major changes to the Company’s oversight framework (abolishing the Supervisory Committee) may be of concern to investors focused on checks and balances within management.
• Currency Exposure: Material sensitivity to foreign exchange movements remains unhedged, leaving earnings vulnerable to currency swings.
• Potential Share Dilution: Significant share issuances through placings in 2025 (over 34 million H Shares) have increased share capital and could have a dilutive effect on existing shareholders.

Conclusion

While InnoScience continues to demonstrate operational growth and an aggressive investment strategy in expanding its production and R&D capabilities, investors should stay vigilant regarding ongoing regulatory compliance challenges, internal control improvements, litigation outcomes, and the Company’s ability to manage financial risks. These issues hold potential to materially impact the Company’s share value in the short to medium term.

Disclaimer

The information above is provided for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. Investors are advised to consult their own financial advisors and consider their own circumstances before making investment decisions. The Company’s future performance is subject to various risks and uncertainties as detailed in its official filings.

View INNOSCIENCE Historical chart here